



IFW  
CP

Attorney Docket No. 2543-1-033

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Jonathan A. Terrett

SERIAL NO.: 10/736,227

EXAMINER: Unassigned

DATE FILED: December 15, 2003


ART UNIT: 1645

FOR: NOVEL CANCER ASSOCIATED PROTEIN

**CERTIFICATE OF MAILING UNDER 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 30, 2004.

Karen Garipoli  
(Name of Depositor)

  
(Signature and Date)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

**INFORMATION DISCLOSURE STATEMENT**

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.

Enclosed please find copies of References **BA** through **CO** listed on the attached Form

PTO-1449. However, with respect to Reference BC, please note that due to the size of the reference (367 pages), a CD containing reference WO 02/64611 in Adobe .pdf format is enclosed in place of a printed copy. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,  
  
David A. Jackson  
Attorney for Applicants  
Registration No. 26,742

KLAUBER & JACKSON  
411 Hackensack Avenue  
Hackensack, New Jersey 07601  
201-487-5800



Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. <b>2543-1-033</b>
		SERIAL NO. <b>10/736,227</b>
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT <b>Jonathan A. Terrett</b>
		FILING DATE <b>December 15, 2003</b>
		GROUP <b>Unknown</b>

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
	BA	WO 01/13117A2 & A3 (EP 1208381)	2/22/01	PCT			
	BB	WO 00/55628 (EP 1159618)	9/21/00	PCT			
	BC	WO 02/64611	8/22/02	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Baselga, J., et al., Recombinant Humanized Anti-HER2 Antibody(Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts <sup>1</sup> , 1998, Cancer Res. 58: 2825-2831
CB	Catimel, B., et al., Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium, 1996, J. Biol. Chem. 271:25664-25670
CC	ABSTRACT for Craggs, et al., 2003, Applied Genomics & Proteomics 2(2):101-100
CD	Davis, ID, et al., An overview of Cancer immunotherapy, 2000, Immunol Cell Biol. 78: 179-196
CE	Dillman, R.O., Perceptions of Herceptin®: A Monoclonal Antibody for the Treatment of Breast Cancer, 1999, Cancer Biother. Radiopharm. 14: 5-10
CF	Green, MC, et al., Monoclonal antibody therapy for solid tumors, 2000, Cancer Treat Rev 26:269-86
CG	Hubert, R.S. et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors, 1999, Pro. Natl Acad. Sci. USA 96: 14523-14528
CH	Knuth, A. et al., Cancer immunotherapy in clinical oncology, 2000, Cancer Chemother. Pharmacol. 46, S46-51

EXAMINER:

DATE CONSIDERED:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;  
 Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO:1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY, DOCKET NO.	2543-1-033
	SERIAL NO.	10/736,227
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
	GROUP	Unknown

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CI	Lucas S., et al., MAGE-5B, MAGE-B6, MAGE-C2, and MAGE-C3: Four New Members Of The MAGE Family With Tumor-Specific Expression, 2000, Int.J. Cancer 87:55-60	
CJ	Miller, K.D., et al., Toward checkmate:biology and breast cancer therapy for the new millennium, 1999, Invest.New Drugs 17: 417-427	
CK	Saffran, D.C., et al., Targget antigens for prostate cancer immunotherapy, 1999, Cancer Metastasis Rev. 18: 437-449	
CL	Shiku, H., et al., Development of a cancer vaccine: peptides, proteins, and DNA 2000, Cancer Chemother. Pharmacol. 46:S77-82	
CM	Stebbing, J., et al., Herceptin (transtuzamab) in advanced breast cancer, 2000, Cancer Treat. Rev. 26:287-290	
CN	Vermeulen, S.J., et al., The $\alpha$ E-catenin gene (CTNNA1) acts as an invasion-suppressor gene in human colon cancer cells, 1999, Oncogene 18: 905-915	
CO	Database EMBL online 1December 2001(2001-12-01)"NSE2 Protein" Database Accession No. Q96Kn1 XP002234948	
EXAMINER:		DATE CONSIDERED:
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609;    Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant</p>		